nCounter® PlexSet™ Reagents
Helping Your Research
Accelerate your cell line screening and high-throughput applications with nCounter PlexSet Reagents for Gene Expression Analysis. PlexSet technology enables multiplexed gene expression assays to be performed more efficiently and cost effectively for projects ranging up to 96 RNA targets. Unlike other gene expression technologies, PlexSet reagents enable researchers to reduce their hands-on time by eliminating the need for cDNA conversion, replicate utilization, or RNA purification. Like other nCounter assays, Plexset reagents provides a simple and robust method for multiplexing targets without the need to optimize probes or amplification conditions.
How It Works
The PlexSet reagents are based on proven nCounter technology utilizing molecular barcodes for highly multiplexed digital analysis.
Multiplex up to 96 custom probes (or choose from preselected pathway panels) across 96 samples to generate 9,216 data points per run with only 30 minutes of hands-on time
Utilization of lysed cells eliminates the need for RNA purification and amplification; save resources with an efficient workflow that does not require cDNA conversions, replicates, or prior probe optimizations
Proven nCounter Digital Gene Expression technology provides excellent precision and reproducibility across a wide dynamic range
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Looking for recommendations on panels in your application area? Check out the NanoString Panel Pro selection tool. Browse our catalog of preselected pathway panels by name, application area, biologic pathway/process, or gene name(s).
- Expertly curated panels covering ~140 biological pathways and fields of interest for human, mouse, and rat samples.
- Each panel contains 90 genes chosen to comprehensively cover each pathway involved in the topic.
- All necessary controls and reference genes are included in each panel.
- Customize by adding additional genes of interest to the panels (or omitting genes that are not of interest).
Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients.
Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa.
Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
PURPOSE: Recently discovered molecular classifications for urothelial bladder cancer appeared to be promising prognostic and predictive biomarkers. The present study was conducted to evaluate the prognostic impact of molecular subtypes assessed by two different methodologies (gene and protein expression), to compare these two approaches and to correlate molecular with histological subtypes in a consecutively collected, mono-institutional muscle-invasive bladder cancer (MIBC) cohort.
Decreased ATM Function Causes Delayed DNA Repair and Apoptosis in Common Variable Immunodeficiency Disorders.
PURPOSE: Common variable immunodeficiency disorders (CVID) is characterized by low/absent serum immunoglobulins and susceptibility to bacterial infection. Patients can develop an infections-only phenotype or a complex disease course with inflammatory, autoimmune, and/or malignant complications.